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Abstract
Objective To present long-term respiratory function outcomes
from an open-label, multi-center, phase 3 extension study
(MOR-005) of elosulfase alfa enzyme replacement therapy
(ERT) in patients with Morquio A syndrome.
Methods In part 1 of MOR-005, patients initially random-
ized to ERT in the 24-week pivotal study (MOR-004)
remained on their regimen (2.0 mg/kg/week or every other
week); placebo patients were re-randomized to one of the
two regimens. During part 2, all patients received
elosulfase alfa 2.0 mg/kg/week. Respiratory function was
one of the efficacy endpoints evaluated in MOR-005.
Change from MOR-004 baseline to 120 weeks of treat-
ment for the combined population was determined and
compared with results from untreated patients from a
Morquio A natural history study (MorCAP).
Results Maximum voluntary ventilation (MVV) improved up
to week 72 and then stabilized; forced vital capacity (FVC)
and forced expiratory volume in 1 s (FEV1) increased contin-
uously over 120 weeks. Mean increases in the modified per-
protocol population was 9.2 % for FVC, 8.8 % for FEV1, and
6.1 % for MVV after 120 weeks. All patients ≤14 years
showed respiratory improvements, presumably in part related
to growth; however, these were greater in treated patients. For
those >14 years, treated patients showed improvements, while
deterioration occurred in untreated. Altogether, the improve-
ments were significantly greater (P < 0.05) in treated patients.
Conclusions Long-term ERT is associated with sustained im-
provements in respiratory function in Morquio A. In younger
patients (≤14 years), some improvement may be ascribed to
growth. In older patients, other mechanisms, e.g., decreased
glycosaminoglycan storage, are likely involved.
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Introduction
Morquio A syndrome (mucopolysaccharidosis (MPS) IVA;
OMIM #253000) is a rare inherited lysosomal storage disor-
der in which deficiency of the lysosomal enzyme N-
acetylgalactosamine-6-sulfatase (GALNS, EC 3.1.6.4) causes
progressive accumulation of the glycosaminoglycans (GAGs)
chondroitin-6-sulfate and keratan sulfate (KS) in tissues and
organs. This accumulation can lead to musculoskeletal abnor-
malities, short trunk, dysfunctions in the respiratory, cardiac,
neurological, and gastrointestinal systems, impaired vision,
and hearing loss (Harmatz et al 2013; Hendriksz et al 2013).
Respiratory manifestations are among the most common
causes of mortality in Morquio A patients (Lavery and
Hendriksz 2015) and include upper and lower airway ob-
struction and restrictive pulmonary disease (Berger et al
2013). Airway obstruction can develop due to GAG accu-
mulation in upper and lower airways and secondary to
inflammation, abnormalities of the spine (e.g., short neck,
high epiglottis, abnormal cervical vertebrae), and abnor-
malities of trachea and main stem bronchii (Simmons
et al 2005; Sims and Kempiners 2007). Restrictive disease
can be due to a reduction of lung volume secondary to
short stature and thoracic cage deformities or impaired mo-
tility of the diaphragm due to liver enlargement or respira-
tory muscle weakness (Berger et al 2013; Harmatz et al
2013; Hendriksz et al 2013). Spinal cord compression
and cardiac disease may also cause or aggravate respiratory
problems (Berger et al 2013). In an early stage, obstructive
and restrictive disease can lead to recurrent airway infec-
tions and sleep disordered breathing (Leighton et al 2001;
Muhlebach et al 2011). Over time, they may lead to day-
time hypoventilation and eventual respiratory failure
(Pelley et al 2007). Respiratory impairment also consider-
ably increases the risk of complications with anesthesia
during surgery (Walker et al 2013).
Currently, the only approved therapy for Morquio A is
elosulfase alfa (Vimizim®, BioMarin Pharmaceutical Inc.,
Novato, CA) enzyme replacement therapy (ERT) (Sanford
and Lo 2014). The efficacy and safety of this therapy has been
established in a 24-week, double blind, randomized, placebo-
controlled, phase 3 study including 176 Morquio A patients
(MOR-004) (Hendriksz et al 2014, 2015). After 24 weeks of
treatment with 2.0 mg/kg/week elosulfase alfa, patients
showed a significant improvement in the 6-min walk test
(6MWT) distance, a numerical improvement in the 3-min stair
climb test (3MSCT), and a significant decline in urine KS
(Hendriksz et al 2014, 2015). The study also showed numer-
ical improvements in respiratory function tests. At 24 weeks,
maximum voluntary ventilation (MVV), forced vital capacity
(FVC), and forced expiratory volume in one second (FEV1)
increased by a mean of 10.3, 3.3, and 1.8 %, respectively,
compared to placebo (Hendriksz et al 2014).
Evaluation of results from the long-term, open-label exten-
sion of MOR-004 (MOR-005) showed an acceptable safety
profile consistent with MOR-004, sustained urine KS reduc-
tion, and sustained improvements in endurance over 2 years in
treated patients when compared to corresponding untreated
patients from the Morquio A Clinical Assessment Program
natural history study (MorCAP, #NCT00787995) (Hendriksz
et al 2016). Here, we present the respiratory function out-
comes after 120 weeks of treatment with elosulfase alfa in
the MOR-005 study.
Methods
Study design
MOR-005 (#NCT01415427) is a multi-national, multi-center,
open-label, phase 3, extension of the randomized, double-
blind, placebo-controlled, 24-week phase 3 study (MOR-
004; #NTC01275066). The 24-week pivotal study included
176Morquio A patients ≥5 years of age (Hendriksz et al 2014,
2015). All patients completing the pivotal study were eligible
for enrolment in the extension study. The study design of
MOR-004 and MOR-005 (Fig. 1) has been previously
discussed in detail (Hendriksz et al 2014, 2016). MOR-005
consisted of two parts. In part 1, patients initially randomized
to elosulfase alfa duringMOR-004 remained on their assigned
dosing regimen of 2.0 mg/kg/week or every other week (qow).
Placebo-treated patients were re-randomized (1:1) to one of
the two dosing regimens. Part 2 started at a specific date when
all patients were switched to elosulfase alfa 2.0 mg/kg/week,
which was established as the recommended dose after review
of the final results of MOR-004. Timing of transition to week-
ly dosing depended on study enrolment timing and ranged
from week 36 to 96.
Evaluation of respiratory function
The respiratory function efficacy evaluations conducted in this
extension study are identical to those conducted during the 24-
week pivotal trial, which have been described in detail previ-
ously (Hendriksz et al 2014). Respiratory function was
assessed as one of the measures of long-term efficacy and tests
included FVC, FEV1, and MVV. These were performed every
24 weeks in part 1 of MOR-005 and every 48 weeks in part 2.
All respiratory function tests were conducted in accordance
with the American Thoracic Society standards (American
Thoracic society 1995).
Due to the long-term nature of this study, a placebo group
was not included. Therefore, respiratory function data from a
comparable untreated patient population from the multi-cen-
ter, cross-sectional MorCAP natural history study (Harmatz
et al 2013, 2015) were used to place the results in the context
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of a progressive disease. MorCAP patients included in the
comparisons with the MOR-005 modified per-protocol
(MPP, see statistical methods for explanation) population
met the inclusion criteria for MOR-005 (≥5 years of age; av-
erage 6MWT distance ≥30 and ≤325 m at baseline), had lon-
gitudinal data (year 1 and/or year 2) available, and reported no
major surgeries during the relevant time period of 2 years.
Statistical methods
The analyzed data were collected during the 24-week MOR-
004 study and 96 weeks of the MOR-005 extension study,
representing a total of up to 120 weeks of ERT (96 weeks
for the patients originally receiving placebo). Results are re-
ported for the intent-to-treat (ITT) and MPP population. The
ITT population includes all patients who were previously in-
cluded in the 24-week MOR-004 study and had received at
least one dose of elosulfase alfa in MOR-005; the MPP pop-
ulation (a subset of the ITT population) excludes patients who
had an orthopedic surgery during the study or exhibited non-
compliance (defined as missing ≥20 % of scheduled infu-
sions). Further details are described in the primary MOR-
005 publication (Hendriksz et al 2016). Descriptive statistics
of respiratory function endpoints are provided for both
populations.
The variable timing of transition to weekly dosing (from
week 36 to week 96) precluded comparison of dosing regi-
mens. However this decision was considered to be in the best
interest of the patients. In addition, comparisons were also
limited by the small sample sizes of the two treatment groups
originally randomized to placebo. Therefore, all groups,
representing patients consistently treated with the more
optimal weekly dosing as well as patients that received qow
dosing, were combined for the analysis.
A repeated measures analysis of covariance (ANCOVA)
model was used to compare least square mean (LS mean)
changes from baseline at year 1 and 2 of the MOR-005 MPP
and MorCAP populations. The model included treatment,
time point, baseline height, treatment and time point interac-
tion, age group, and baseline measurement. Correlations be-
tween change in FVC and change in height were estimated
using the Pearson correlation coefficient (r).
Results
Patient characteristics
Of the 175 patients who completed the 24-week pivotal study
(MOR-004), 173 enrolled in the MOR-005 extension study
(Hendriksz et al 2016). Of the 353 untreated patients in
MorCAP, 79 met the inclusion criteria for comparison with
the MOR-005 MPP population. The exact time of follow-up
visits in MorCAP varied; visit windows ranged from approx-
imately 38 to 87 weeks (mean follow-up 63.7 weeks or
446 days) for the year 1 evaluation and approximately 87 to
135 weeks (mean follow-up 107 weeks or 749 days) for the
year 2 evaluation. These were compared with the 72 and
120 week time points of MOR-004/MOR-005.
Supplementary Table 1 shows demographics and baseline
characteristics of patients who entered MOR-005 and of the
untreated patients from the MorCAP study used for compari-
son. For MorCAP patients, baseline data are shown for all
patients contributing data at baseline and separately for pa-
tients contributing data at year 1 and/or year 2. Both patient
Fig. 1 Study design of MOR-004 and MOR-005. Of the 176 patients enrolled in MOR-004, 175 completed the MOR-004 and one withdrew after a
single infusion. Of these, 173 patients continued into MOR-005 and two declined to provide informed consent for the extension study
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populations had similar baseline characteristics (see Table 1
for respiratory function baseline values), regardless of the time
point of comparison.
Respiratory function over 120 weeks
During the 24-week pivotal study, numerical improvements in
FVC, FEV1, and MVV were observed compared to placebo
(Hendriksz et al 2014). During MOR-005, FVC and FEV1
continuously increased up to week 120 (Fig. 2). MVV contin-
ued to improve during the extension study up to week 72, and
then stabilized by week 120 (Fig. 2). The mean (SE) FEV1/
FVC ratio for theMOR-005MPP population was 0.9 (0.01) at
baseline and remained constant over time.
Figure 2 and Table 1 show changes in respiratory function
outcomes fromMOR-004 baseline over 120 weeks in the ITT
and MPP populations.
Respiratory function in treated patients versus untreated
natural history controls
ANCOVA analysis demonstrated significant improvements
from baseline in the MOR-005 MPP population versus corre-
sponding untreated patients from the MorCAP natural history
study for FVC, FEV1, and MVV at 1 and 2 years (P < 0.05)
(Fig. 3a). A similar, though not consistently significant, trend
was seen for percent changes from baseline (Fig. 3b). LS
mean changes from MOR-004 baseline in FVC were
+0.0589 L (7.6%) and +0.0827 L (8.8%) inMOR-005 versus
+0.0008 L (2.2%) and −0.0299 L (2.6%) inMorCAP at years
1 and 2, respectively. LS mean changes in FEV1 were
+0.0385 L (6.3 %) and +0.06 L (8.5 %) in MOR-005 versus
−0.0399 L (0.9 %) and -0.052 L (−0.6 %) inMorCAP at years
1 and 2, respectively. LS mean changes in MVV were +1.7 L/
min (9.6 %) and +2.1 L/min (7.3 %) in MOR-005 versus
−2.4 L/min (0.8 %) and −5.2 L/min (−7.0 %) in MorCAP at
years 1 and 2, respectively. The mean (SE) FEV1/FVC ratio at
baseline for MorCAPwas the same as for MOR-005MPP, 0.9
(0.01), and did not change over time.
ANCOVA analyses of FVC and FEV1 were also performed
for patient subgroups ≤14 and >14 years, as growth is limited
beyond the age of 14 in Morquio A patients (Harmatz et al
2015). Both FVC and FEV1 improved in MOR-005 MPP pa-
tients versus the untreated MorCAP population, regardless of
age group (Fig. 3c). In the ≤14 years subgroup, both treated and
untreated patients showed improvements, presumptively due to
growth; however, the improvements were greater in treated
patients. In this ≤14 years subgroup, the MOR-005 MPP pa-
tients (N = 67) had a mean change (SE) in height of +5.1 (3.5)
cm compared to +2.8 (2.8) cm in the untreated MorCAP pa-
tients (N = 12). In the >14 years subgroup, treated patients
showed an improvement in respiratory function while deterio-
ration occurred in untreated patients. A difference was also Ta
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observed in mean change (SE) in height, +1.3 (3.2) cm in the
MOR-005MPP (N = 43) patients compared to −0.0 (0.9) cm in
the untreated MorCAP patients (N = 10). In younger patients,
improvements in FVC correlated with increases in height
(MOR-005 r = 0.32 and MorCAP r = 0.43; Supplementary
Fig. 1A). However, in older patients, no correlation was evident
(MOR-005 r = 0.14 and MorCAP r = −0.22; Supplementary
Fig. 1B), suggesting involvement of other mechanisms.
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Discussion
ERT with elosulfase alfa is the only approved treatment for
patients with Morquio A targeting the underlying cause of the
disease, GALNS deficiency. Previously published data from
MOR-005 have shown that long-term treatment with elosulfase
alfa is associated with significant improvements in endurance
measures and a decrease in urine KS for up to 120 weeks, when
compared to untreated patients from the MorCAP natural his-
tory study (Hendriksz et al 2016). The results of the present
analysis indicate that elosulfase alfa is associated with long-
term sustained improvement in respiratory function as well.
MVV increased rapidly in the first 24 weeks and kept im-
proving until 72 weeks, after which it stabilized. The positive
trends in FVC and FEV1 observed during the pivotal study
(Hendriksz et al 2014) continued during the extension study
for up to 120 weeks, although at a slower initial improvement
rate than MVV. This slower rate of improvement in FVC and
FEV1 compared to MVV highlights that some pulmonary
functions require longer periods of treatment to show im-
provement, similar to observations for MPS VI (Harmatz
et al 2010).
The observed improvement in respiratory function over a
2-year period is remarkable considering the progressive nature
of Morquio A, which leads to worsening of respiratory func-
tion with increasing age (Tomatsu et al 2011; Hendriksz et al
2013). The decline that is observed over a 2-year period in
untreated patients underpins the significance of the improve-
ments that are observed in this study. Given the morbidity and
mortality associated with decreasing respiratory function in
Morquio A (Lavery and Hendriksz 2015), the improvements
reported here are particularly meaningful.
There was no placebo group included as continuing with
weekly placebo infusions and withholding treatment for the
duration of this long-term extension study was considered
unethical. In the absence of a placebo group, the MOR-005
data were compared to that of a similar untreated Morquio A
patient population from the MorCAP natural history study.
The improvements from baseline in respiratory function out-
comes in MOR-005 differed significantly from the gradual
decline seen in the MorCAP population, suggesting that
elosulfase alfa slows down, and even reverses the natural pro-
gression of respiratory dysfunction. The interpretation of the
results was complicated by differences in timing of transition
from elosulfase alfa qow to weekly dosing, which depended
on study enrolment timing and ranged from week 36 to week
96. Therefore, a proportion of the patients in MOR-005 had
only been on weekly dosing for 26 weeks. This may have
biased analysis in favor of finding no effect of treatment since
qow dosing was found to be suboptimal based on the pivotal
MOR-004 trial results (Hendriksz et al 2016). Due to the stag-
gered transition, the effect of long-term qow treatment alone
could not be accurately assessed and any conclusions drawn
would be speculative in nature. Limitations of the comparison
with patients from the MorCAP study have been discussed
previously and include the decreasing number of observations
over time in the MorCAP population, potential differences
that may exist between the MorCAP and MOR-005 popula-
tions and test executions, and the fact that some patients con-
tribute to both populations (Hendriksz et al 2016). Despite
this, baseline demographics and characteristics of the popula-
tions used in the analyses were relatively similar.
FVC, FEV1, and MVVassessments are physically demand-
ing tests as they require maximal effort, which can be challeng-
ing forMPS patients that have limited lung capacity due to their
short stature, chest wall deformities, respiratory muscle weak-
ness, and upper airway obstruction (Berger et al 2013; Harmatz
et al 2013; Hendriksz et al 2013). The observed increase in
respiratory function in theMOR-005 population may be direct-
ly or indirectly attributed to several mechanical, physiological,
and/or anatomical factors. As lung volume is related to body
size, growth may be an important factor in younger patients.
The small increases in FVC and FEV1 over 2 years seen in
untreated MorCAP patients ≤14 years old are likely due, in
large part, to growth. Improvements in FVC correlated with
increases in height in these patients. Increases in FVC and
FEV1 were greater in treated patients than in untreated patients.
This may be caused in part by ERT-induced growth accelera-
tion, as treated patients showed an increase in height of +5.1 cm
over 2 years compared to only +2.8 cm in the untreated pa-
tients. However, FVC and FEV1 also improved in ERT-treated
patients >14 years, while the untreatedMorCAP patients in this
age group showed considerable decline. Growth was very lim-
ited in older patients (+1.3 cm in treated vs -0.0 cm in untreat-
ed) suggesting that the increase in respiratory function by ERT
was most likely mediated by other mechanisms, such as de-
creased upper airway obstruction, increased chest wall compli-
ance, improved respiratory muscle strength, and/or improved
diaphragmatic movement due to a reduction in liver size and a
declined GAG tissue storage (Harmatz et al 2010). These
mechanisms may, in addition to growth, also have contributed
to the improved respiratory function in younger patients.
Compared with FVC and FEV1, MVV increased relatively
rapidly in our study, particularly during the first 24 weeks, but
stabilized after 72 weeks. A similar pattern of early response
has been reported for MPS VI patients treated with ERT
(Harmatz et al 2010). Even though MVV generally shows a
Fig. 3 Least square (LS) mean respiratory function changes fromMOR-
004 baseline in the MOR-005 modified per-protocol (MPP; green bars)
population treated with elosulfase alfa versus corresponding untreated
patients from the MorCAP (gray bars) natural history study (ANCOVA
analysis). a FVC, FEV1, and MVV LS mean change from baseline b
FVC, FEV1, and MVV LS mean percent change from baseline c FVC
and FEV1 LS mean change from baseline in patients aged ≤14 years and
>14 years. Error bars represent standard error; Ns are shown at the bottom
of each graph
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good correlation with FEV1 (Pellegrino et al 2005), in patients
with neuromuscular disease or upper airway obstruction a
disproportional change in MVV relative to FEV1 has been
observed (Engström et al 1964; Serisier et al 1982; Braun
et al 1983). One possible explanation for our results is that
ERT reduced airway obstruction. However, that is not sup-
ported by the observation that FEV1/FVC ratios remained
stable throughout the study, whereas a reduced FEV1/FVC
ratio suggests obstructive disease (Pellegrino et al 2005;
Berger et al 2013). Therefore, the most probable cause of
respiratory dysfunction in the study population is restrictive
lung disease. This respiratory limitation is likely not only due
to a low FVC, caused by the severe skeletal involvement in
Morquio A (Muhlebach et al 2011; Harmatz et al 2013), but
also the inability to increase respiratory rate due to muscle
weakness, pain, and joint constriction. Improvement in respi-
ratory rate can be attributed to both modestly improved FVC
and FEV1 but also to improved MVVafter ERT treatment.
Improvement and long-term stabilization of respiratory func-
tion with ERT has already been described for MPS I, II, and VI
(Wraith et al 2004; Muenzer et al 2006, 2011; Clarke et al 2009;
Harmatz et al 2010; Lin et al 2014). These results, together with
the results of this study, suggest that the positive effect of ERTon
respiratory function in MPS patients is probably caused by a
variety of mechanisms associated with a decrease in GAG stor-
age, including improvement of joint mobility, reduction in liver
volume, improvement in endurance and respiratory muscle
strength (Wraith et al 2004; Clarke et al 2009; Harmatz et al
2010; Muenzer et al 2011; Hendriksz et al 2016), reduced local
inflammation, and an improvement of lung parenchyma
(Yasuda et al 2013). All these mechanisms can contribute to
improved neuromuscular function, leading to enhanced inspira-
tory effort and thus decreased pulmonary restriction.
Conclusions
Impaired respiratory function is one of the leading causes of
morbidity and mortality in Morquio A patients. The present
study suggests that ERTwith elosulfase alfa slows down, and
partially reverses, the natural progression of respiratory dys-
function associated with Morquio A over a 2 year period.
ERT-induced growth acceleration may considerably contrib-
ute to this effect in younger patients; it is likely that other
mechanisms, related to decreasing GAG accumulation, also
play a role in older patients. Over time, these improvements in
respiratory function may lead to reductions in morbidity and
mortality in Morquio A patients.
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